Savara (STU:YB4P) Total Liabilities : €33.52 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Savara Total Liabilities?

Savara's Total Liabilities for the quarter that ended in Mar. 2024 was €33.52 Mil.

Savara's quarterly Total Liabilities increased from Sep. 2023 (€33.29 Mil) to Dec. 2023 (€34.11 Mil) but then declined from Dec. 2023 (€34.11 Mil) to Mar. 2024 (€33.52 Mil).

Savara's annual Total Liabilities increased from Dec. 2021 (€28.41 Mil) to Dec. 2022 (€30.21 Mil) and increased from Dec. 2022 (€30.21 Mil) to Dec. 2023 (€34.11 Mil).

Savara Total Liabilities Historical Data

The historical data trend for Savara's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Total Liabilities Chart

Savara Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

31.06

27.42

28.41

30.21

34.11

Savara Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															29.05	29.65	33.29	34.11	33.52

Savara Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Savara's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.717	+	(24.161	+	0.227
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	34.11

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	162.826	-	128.721
	=	34.11

Savara's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.025	+	(24.303	+	0.191
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	33.52

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	145.631	-	112.112
	=	33.52

Savara Total Liabilities Related Terms

Thank you for viewing the detailed overview of Savara's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Savara (STU:YB4P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (STU:YB4P) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SVRA:USA

Address

6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746

Website

https://www.savarapharma.com

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara (STU:YB4P) Headlines

No Headlines